Logo image of LXRX

LEXICON PHARMACEUTICALS INC (LXRX) Stock Fundamental Analysis

NASDAQ:LXRX - Nasdaq - US5288723027 - Common Stock - Currency: USD

0.5098  +0.01 (+1.96%)

After market: 0.51 +0 (+0.04%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to LXRX. LXRX was compared to 568 industry peers in the Biotechnology industry. LXRX may be in some trouble as it scores bad on both profitability and health. LXRX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LXRX has reported negative net income.
In the past year LXRX has reported a negative cash flow from operations.
LXRX had negative earnings in each of the past 5 years.
LXRX had a negative operating cash flow in each of the past 5 years.
LXRX Yearly Net Income VS EBIT VS OCF VS FCFLXRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -67.15%, LXRX is doing worse than 63.73% of the companies in the same industry.
LXRX's Return On Equity of -137.31% is on the low side compared to the rest of the industry. LXRX is outperformed by 61.62% of its industry peers.
Industry RankSector Rank
ROA -67.15%
ROE -137.31%
ROIC N/A
ROA(3y)-65.6%
ROA(5y)-57.94%
ROE(3y)-138.18%
ROE(5y)-105.86%
ROIC(3y)N/A
ROIC(5y)N/A
LXRX Yearly ROA, ROE, ROICLXRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

LXRX has a Gross Margin of 98.02%. This is amongst the best in the industry. LXRX outperforms 96.65% of its industry peers.
LXRX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for LXRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 98.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.67%
GM growth 5Y-0.19%
LXRX Yearly Profit, Operating, Gross MarginsLXRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K -100K

More info and screens

3

2. Health

2.1 Basic Checks

LXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LXRX has been increased compared to 1 year ago.
The number of shares outstanding for LXRX has been increased compared to 5 years ago.
Compared to 1 year ago, LXRX has an improved debt to assets ratio.
LXRX Yearly Shares OutstandingLXRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
LXRX Yearly Total Debt VS Total AssetsLXRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -9.77, we must say that LXRX is in the distress zone and has some risk of bankruptcy.
LXRX's Altman-Z score of -9.77 is on the low side compared to the rest of the industry. LXRX is outperformed by 73.59% of its industry peers.
LXRX has a Debt/Equity ratio of 0.69. This is a neutral value indicating LXRX is somewhat dependend on debt financing.
LXRX has a worse Debt to Equity ratio (0.69) than 76.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF N/A
Altman-Z -9.77
ROIC/WACCN/A
WACC11.95%
LXRX Yearly LT Debt VS Equity VS FCFLXRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

LXRX has a Current Ratio of 5.44. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of LXRX (5.44) is comparable to the rest of the industry.
LXRX has a Quick Ratio of 5.44. This indicates that LXRX is financially healthy and has no problem in meeting its short term obligations.
LXRX has a Quick ratio of 5.44. This is comparable to the rest of the industry: LXRX outperforms 59.68% of its industry peers.
Industry RankSector Rank
Current Ratio 5.44
Quick Ratio 5.44
LXRX Yearly Current Assets VS Current LiabilitesLXRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 20.00% over the past year.
Looking at the last year, LXRX shows a very strong growth in Revenue. The Revenue has grown by 2485.77%.
Measured over the past years, LXRX shows a very negative growth in Revenue. The Revenue has been decreasing by -37.35% on average per year.
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55%
Revenue 1Y (TTM)2485.77%
Revenue growth 3Y369.67%
Revenue growth 5Y-37.35%
Sales Q2Q%3682.62%

3.2 Future

Based on estimates for the next years, LXRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.99% on average per year.
The Revenue is expected to grow by 75.28% on average over the next years. This is a very strong growth
EPS Next Y40.07%
EPS Next 2Y21.25%
EPS Next 3Y15.43%
EPS Next 5Y16.99%
Revenue Next Year-16.08%
Revenue Next 2Y17.08%
Revenue Next 3Y50.2%
Revenue Next 5Y75.28%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LXRX Yearly Revenue VS EstimatesLXRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
LXRX Yearly EPS VS EstimatesLXRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.5 -0.5 1 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LXRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LXRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXRX Price Earnings VS Forward Price EarningsLXRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXRX Per share dataLXRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as LXRX's earnings are expected to grow with 15.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.25%
EPS Next 3Y15.43%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LXRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXICON PHARMACEUTICALS INC

NASDAQ:LXRX (4/17/2025, 8:00:00 PM)

After market: 0.51 +0 (+0.04%)

0.5098

+0.01 (+1.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)05-01 2025-05-01/bmo
Inst Owners84.5%
Inst Owner Change0.04%
Ins Owners0.74%
Ins Owner Change0.25%
Market Cap184.29M
Analysts78.33
Price Target2.65 (419.81%)
Short Float %13.29%
Short Ratio6.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)11.71%
Min EPS beat(2)-7.28%
Max EPS beat(2)30.7%
EPS beat(4)3
Avg EPS beat(4)8.95%
Min EPS beat(4)-7.28%
Max EPS beat(4)30.7%
EPS beat(8)6
Avg EPS beat(8)4.16%
EPS beat(12)9
Avg EPS beat(12)2.48%
EPS beat(16)13
Avg EPS beat(16)4.79%
Revenue beat(2)1
Avg Revenue beat(2)130.15%
Min Revenue beat(2)-41.43%
Max Revenue beat(2)301.73%
Revenue beat(4)1
Avg Revenue beat(4)49.1%
Min Revenue beat(4)-42.95%
Max Revenue beat(4)301.73%
Revenue beat(8)2
Avg Revenue beat(8)49.54%
Revenue beat(12)2
Avg Revenue beat(12)-0.31%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-27.78%
PT rev (3m)-27.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.2%
EPS NY rev (1m)19.91%
EPS NY rev (3m)18.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-56.33%
Revenue NY rev (1m)-29.95%
Revenue NY rev (3m)-29.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.93
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 1.82
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.5
FCFYN/A
OCF(TTM)-0.49
OCFYN/A
SpS0.09
BVpS0.4
TBVpS0.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -67.15%
ROE -137.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 98.02%
FCFM N/A
ROA(3y)-65.6%
ROA(5y)-57.94%
ROE(3y)-138.18%
ROE(5y)-105.86%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.67%
GM growth 5Y-0.19%
F-Score5
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 193.07%
Cap/Sales 3.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.44
Quick Ratio 5.44
Altman-Z -9.77
F-Score5
WACC11.95%
ROIC/WACCN/A
Cap/Depr(3y)200.97%
Cap/Depr(5y)201.27%
Cap/Sales(3y)447.45%
Cap/Sales(5y)348.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55%
EPS Next Y40.07%
EPS Next 2Y21.25%
EPS Next 3Y15.43%
EPS Next 5Y16.99%
Revenue 1Y (TTM)2485.77%
Revenue growth 3Y369.67%
Revenue growth 5Y-37.35%
Sales Q2Q%3682.62%
Revenue Next Year-16.08%
Revenue Next 2Y17.08%
Revenue Next 3Y50.2%
Revenue Next 5Y75.28%
EBIT growth 1Y-14.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-10.43%
OCF growth 3YN/A
OCF growth 5YN/A